Abstract:The mammalian target of rapamycin is a serine-threonine kinase that regulates cell cycle progression. Rapamycin and its analogues inhibit the mammalian target of rapamycin and are being actively investigated in clinical trials as novel targeted anticancer agents. Although cyclin D1 is down-regulated by rapamycin, the role of this down-regulation in rapamycin-mediated growth inhibition and the mechanism of cyclin D1 down-regulation are not well understood. Here, we show that overexpression of cyclin D1 partially overcomes rapamycin-induced cell cycle arrest and inhibition of anchorage-dependent growth in breast cancer cells. Rapamycin not only decreases endogenous cyclin D1 levels but also decreases the expression of transfected cyclin D1, suggesting that this is at least in part caused by accelerated proteolysis. Indeed, rapamycin decreases the half-life of cyclin D1 protein, and the rapamycin-induced decrease in cyclin D1 levels is partially abrogated by proteasome inhibitor N-acetyl-leucyl-leucyl-norleucinal. Rapamycin treatment leads to an increase in the kinase activity of glycogen synthase kinase 3β (GSK3β), a known regulator of cyclin D1 proteolysis. Rapamycin-induced down-regulation of cyclin D1 is inhibited by the GSK3β inhibitors lithium chloride, SB216763, and SB415286. Rapamycin-induced G1 arrest is abrogated by nonspecific GSK3β inhibitor lithium chloride but not by selective inhibitor SB216763, suggesting that GSK3β is not essential for rapamycin-mediated G1 arrest. However, rapamycin inhibits cell growth significantly more in GSK3β wild-type cells than in GSK3β-null cells, suggesting that GSK3β enhances rapamycin-mediated growth inhibition. In addition, rapamycin enhances paclitaxel-induced apoptosis through the mitochondrial death pathway; this is inhibited by selective GSK3β inhibitors SB216763 and SB415286. Furthermore, rapamycin significantly enhances paclitaxel-induced cytotoxicity in GSK3β wild-type but not in GSK3β-null cells, suggesting a critical role for GSK3β in rapamycin-mediated paclitaxel-sensitization. Taken together, these results show that GSK3β plays an important role in rapamycin-mediated cell cycle regulation and chemosensitivity and thus significantly potentiates the antitumor effects of rapamycin.

Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway

Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins

TOR controls translation initiation and early G1 progression in yeast

Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast

Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression

The histone H2B Arg95 residue links the pheromone response pathway to rapamycin-induced G1 arrest in yeast

Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity

Genetic defects in SAPK signalling, chromatin regulation, vesicle transport and CoA-related lipid metabolism are rescued by rapamycin in fission yeast

Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells

The Role of GSK3β in Rapamycin-Mediated Cell Cycle Regulation

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Rapamycin Inhibiting Jurkat T Cells Viability Through Changing Mrna Expression of Serine/Threonine Protein Phosphatase 2A

Role of Glycogen Synthase Kinase 3β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity

Immunopharmacology of rapamycin (A review)

Yeast Crf1p is an activator with different roles in regulation of target genes

Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast

Requirement of the Mtor Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells

Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.

Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression.

General Control Nonderepressible 2 (gcn2) Kinase Inhibits Target of Rapamycin Complex 1 in Response to Amino Acid Starvation in Saccharomyces Cerevisiae

Rapamycin-mediated mTOR inhibition impairs silencing of sex chromosomes and the pachytene piRNA pathway in the mouse testis